Stifel lowered the firm’s price target on Boston Scientific (BSX) to $110 from $125 and keeps a Buy rating on the shares following the company’s quarterly report. Investors seem likely to wait for more visible signs of stability and a “what’s next” catalyst before “enthusiastically embracing the stock again,” the analyst contends.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $94 from $125 at Wells Fargo
- Boston Scientific price target lowered to $99 from $112 at Goldman Sachs
- Boston Scientific price target lowered to $100 from $115 at TD Cowen
- Boston Scientific price target lowered to $101 from $118 at Baird
- Boston Scientific price target lowered to $120 from $140 at UBS